| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,577,816 | -4,704,147 |
| Change in fair value of warrant liability | -858 | -858 |
| Change in fair value of investment option liability | 1,707 | 1,707 |
| Stock-based compensation | 587,089 | 400,108 |
| Amortization of intangibles | 42,180 | 42,180 |
| Depreciation expense | 119,193 | 78,824 |
| Other | -128,683 | - |
| Prepaid expenses and other current assets | -132,795 | -48,192 |
| Accounts payable, accrued expenses and other current liabilities | -295,982 | -11,300 |
| Due to related parties | -232,891 | -133,016 |
| Net cash used in operating activities | -6,356,680 | -4,281,724 |
| Proceeds from sale of common stock and warrants, net of offering costs | 4,244,467 | 4,244,467 |
| Proceeds from the subscription receivable related to the issuance of inducement warrants and the exercise of warrants and preferred investment options | - | 0 |
| Proceeds from common stock sold under the equity distribution agreement, net of offering costs | - | 0 |
| Payment for offering costs previously accrued | - | 0 |
| Proceeds from common stock sold for cash pursuant to the atm agreement, net of offering costs | 1,636,799 | 578,499 |
| Proceeds from the exercise of warrants, net of offering costs | 2,009,095 | 75,044 |
| Net cash provided by financing activities | 7,890,361 | 4,898,010 |
| Effect of foreign exchange rate on changes on cash | -17,113 | -7,496 |
| Net increase in cash | 1,516,568 | 608,790 |
| Cash and cash equivalents at beginning of period | 2,241,026 | - |
| Cash and cash equivalents at end of period | 3,757,594 | - |
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)